TTrialPathMatch Me to Trials
← Back to trials
RecruitingPsoriasis of Scalp

Immune Spatial Features of Guselkumab Cutaneous Response

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

Sponsor: University of California, San Francisco

You may not qualify if…

  • ✕ 1. taking systemic immunosuppressives in the last 4 weeks
  • ✕ 2. pregnancy
  • ✕ 3. severe immunodeficiency (either from genetic or infectious causes).
  • ✕ 4. tuberculosis or other active serious infection
  • ✕ 5. active systemic malignancy.
  • ✕ 6. breast-feeding
  • ✕ 7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  • ✕ 8. Males who are trying to conceive

Where it's recruiting

California

San Francisco

Source: ClinicalTrials.gov · NCT05858632 · last updated 2026-06-04

Immune Spatial Features of Guselkumab Cutaneous Response · TrialPath